{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:35:19Z","timestamp":1751376919613,"version":"3.41.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Considerable interpatient and interoccasion variability has been reported in tacrolimus pharmacokinetics (PK) in the pediatric renal transplant population. This study investigated tacrolimus PK in a 2-year-old post\u2013renal transplant patient and a known CYP3A5 expresser who developed posterior reversible encephalopathy syndrome (PRES) and had significantly elevated tacrolimus blood concentrations during tacrolimus treatment. A model-informed PK assessment was performed to assist with precision dosing. Tacrolimus clearance was evaluated both before and after the development of PRES on post-transplant day (PTD) 26.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective chart review was conducted to gather dosing data and tacrolimus concentrations, as part of a clinical pharmacology consultation service. Individual PK parameters were estimated by Bayesian estimation using a published pediatric PK model. Oral clearance (CL\/F) was estimated for 3 distinct periods\u2014before CNS symptoms (PTD 25), during the PRES event (PTD 27\u201330), and after oral tacrolimus was restarted (PTD 93).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Bayesian estimation showed an estimated CL\/F of 15.0 L\/h in the days preceding the PRES event, compared with a population mean of 16.3 L\/h (95% confidence interval 14.9\u201317.7 L\/h) for CYP3A5 expressers of the same age and weight. Samples collected on PTD 27\u201330 yielded an estimated CL\/F of 3.6 L\/h, a reduction of 76%, coinciding with clinical confirmation of PRES and therapy discontinuation. On PTD 93, an additional assessment showed a stable CL\/F value of 14.5 L\/h 1 month after reinitiating tacrolimus and was used to recommend a continued maintenance dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This is the first report to demonstrate acutely decreased tacrolimus clearance in PRES, likely caused by the downregulation of metabolizing enzymes in response to inflammatory cytokines. The results suggest the ability of model-informed Bayesian estimation to characterize an acute decline in oral tacrolimus clearance after the development of PRES and the role that PK estimation may play in supporting dose selection and individualization.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001045","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T20:23:22Z","timestamp":1675369402000},"page":"376-382","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Model-Informed Estimation of Acutely Decreased Tacrolimus Clearance and Subsequent Dose Individualization in a Pediatric Renal Transplant Patient With Posterior Reversible Encephalopathy Syndrome"],"prefix":"10.1097","volume":"45","author":[{"given":"Bradley","family":"Miyagawa","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center;"},{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Lazear","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Cincinnati Children's Hospital Medical Center;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Hooper","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center;"},{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center;"},{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-9826","authenticated-orcid":false,"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center;"},{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"432","DOI":"10.5414\/CN107610","article-title":"Treatment of childhood nephrotic syndrome with long-term, low-dose tacrolimus","volume":"79","author":"Bock","year":"2013","journal-title":"Clin Nephrol."},{"key":"R2-20250603","first-page":"62","article-title":"Pediatric renal transplantation","volume":"3","author":"Saeed","year":"2012","journal-title":"Int J Organ Transpl Med"},{"key":"R3-20250603","first-page":"485","article-title":"A review on therapeutic drug monitoring of immunosuppressant drugs","volume":"14","author":"Mohammadpour","year":"2011","journal-title":"Iran J Basic Med Sci."},{"issue":"3","key":"R4-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr Drug Metab."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1399-0012.2009.01181.x","article-title":"Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation","volume":"24","author":"Yanagimachi","year":"2010","journal-title":"Clin Transpl."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/jlts.2001.27475","article-title":"Neurotoxicity of immunosuppressive drugs","volume":"7","author":"Wijdicks","year":"2001","journal-title":"Liver Transpl."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/17425255.2016.1170808","article-title":"Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations","volume":"12","author":"Tang","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","article-title":"Clinical determinants of calcineurin inhibitor disposition: a mechanistic review","volume":"48","author":"Vanhove","year":"2016","journal-title":"Drug Metab Rev."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/TP.0b013e318247a6c7","article-title":"Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation","volume":"93","author":"Hooper","year":"2012","journal-title":"Transplant."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin Chem."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/psp4.12392","article-title":"A theoretical physiologically-based pharmacokinetic approach to ascertain covariates explaining the large interpatient variability in tacrolimus disposition","volume":"8","author":"Emoto","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-017-0567-8","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation","volume":"57","author":"Andrews","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"e3173","DOI":"10.1097\/MD.0000000000003173","article-title":"Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review","volume":"95","author":"Song","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.mehy.2012.11.028","article-title":"Posterior reversible encephalopathy syndrome in the setting of COPD: proposed pathogenesis","volume":"80","author":"Dardis","year":"2013","journal-title":"Med Hypotheses."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/cei.13095","article-title":"Differential serum cytokine profile in patients with systemic lupus erythematosus and posterior reversible encephalopathy syndrome","volume":"192","author":"Merayo-Chalico","year":"2018","journal-title":"Clin Exp Immunol."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bcpt.13539","article-title":"Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: effect of interleukin 6-induced suppression of the cytochrome P450 3A gene","volume":"128","author":"Enokiya","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FTD.0b013e318285e779","article-title":"Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure","volume":"35","author":"Saint-Marcoux","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FTD.0b013e31819c6a37","article-title":"Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay","volume":"31","author":"Wallemacq","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/bcp.13960","article-title":"Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients","volume":"85","author":"Riff","year":"2019","journal-title":"Br J Clin Pharmacol."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40262-019-00831-8","article-title":"A population pharmacokinetic model does not predict the optimal starting dose of tacrolimus in pediatric renal transplant recipients in a prospective study: lessons learned and model improvement","volume":"59","author":"Andrews","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"R24-20250603","first-page":"375263","article-title":"Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipients","volume":"2013","author":"Jantz","year":"2013","journal-title":"Case Rep Transpl."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","article-title":"A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6","volume":"94","author":"Machavaram","year":"2013","journal-title":"Clin Pharmacol Ther."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment","volume":"215","author":"Stanke-Labesque","year":"2020","journal-title":"Pharmacol Ther."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3174\/ajnr.A0960","article-title":"Posterior reversible encephalopathy syndrome after solid organ transplantation","volume":"29","author":"Bartynski","year":"2008","journal-title":"AJNR Am J Neuroradiol."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.transproceed.2017.09.019","article-title":"Impact of acute infection requiring hospitalization on tacrolimus blood levels in kidney transplant recipients","volume":"49","author":"Percy","year":"2017","journal-title":"Transpl Proc."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejps.2018.12.004","article-title":"Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia","volume":"128","author":"Mizuno","year":"2019","journal-title":"Eur J Pharm Sci."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bcp.13459","article-title":"Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure","volume":"84","author":"Brussee","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/FTD.0000000000000761","article-title":"Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions","volume":"42","author":"Elens","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/cpt.2402","article-title":"Physiologically based pharmacokinetic modelling to investigate the impact of the cytokine storm on CYP3A drug pharmacokinetics in COVID-19 patients","volume":"111","author":"Stader","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/cpt.2146","article-title":"Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail","volume":"109","author":"Lenoir","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.ejps.2017.05.037","article-title":"Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies","volume":"109S","author":"Mizuno","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.2012.109","article-title":"In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients","volume":"92","author":"de Jonge","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/jcph.1118","article-title":"Tacrolimus population pharmacokinetics and multiple CYP3A5 genotypes in black and white renal transplant recipients","volume":"58","author":"Campagne","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/ijms19030882","article-title":"Prediction of tacrolimus exposure by CYP3A5 genotype and exposure of co-administered everolimus in Japanese renal transplant recipients","volume":"19","author":"Kagaya","year":"2018","journal-title":"Int J Mol Sci."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1208\/s12248-017-0119-z","article-title":"Clinical evaluation of modified release and immediate release tacrolimus formulations","volume":"19","author":"Tremblay","year":"2017","journal-title":"AAPS J."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jcpt.13093","article-title":"Immunosuppressives and enteral feeding tubes: an integrative review","volume":"45","author":"Silva","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/00912700122009999","article-title":"Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol."},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/ajt.12061","article-title":"Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation","volume":"13","author":"Barbas","year":"2013","journal-title":"Am J Transpl."},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00007.x","article-title":"Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients","volume":"48","author":"Bottiger","year":"1999","journal-title":"Br J Clin Pharmacol."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"e2014014","DOI":"10.4084\/mjhid.2014.014","article-title":"Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review","volume":"6","author":"Apuri","year":"2014","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00007890-199402270-00008","article-title":"FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects","volume":"57","author":"Backman","year":"1994","journal-title":"Transplant."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11916-020-00932-1","article-title":"Posterior reversible encephalopathy syndrome","volume":"25","author":"Gewirtz","year":"2021","journal-title":"Curr Pain Headache Rep."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.clineuro.2010.07.023","article-title":"Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors","volume":"112","author":"Burnett","year":"2010","journal-title":"Clin Neurol Neurosurg."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.1111\/petr.12039","article-title":"Posterior reversible encephalopathy syndrome and hemorrhage associated with tacrolimus in a pediatric heart transplantation recipient","volume":"17","author":"Loar","year":"2013","journal-title":"Pediatr Transpl."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/bcp.14426","article-title":"Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care","volume":"88","author":"Mizuno","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ajh.25510","article-title":"Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia","volume":"94","author":"McGann","year":"2019","journal-title":"Am J Hematol."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.12851","article-title":"Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia","volume":"81","author":"Dong","year":"2016","journal-title":"Br J Clin Pharmacol."},{"issue":"suppl 1","key":"R53-20250603","first-page":"S36","article-title":"Status toward the implementation of precision dosing in children","volume":"61","author":"Barrett","year":"2021","journal-title":"J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:07:17Z","timestamp":1748970437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001045","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"2022-05-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}